160 related articles for article (PubMed ID: 26865565)
1. Aurora kinase inhibitor nanoparticles target tumors with favorable therapeutic index in vivo.
Ashton S; Song YH; Nolan J; Cadogan E; Murray J; Odedra R; Foster J; Hall PA; Low S; Taylor P; Ellston R; Polanska UM; Wilson J; Howes C; Smith A; Goodwin RJ; Swales JG; Strittmatter N; Takáts Z; Nilsson A; Andren P; Trueman D; Walker M; Reimer CL; Troiano G; Parsons D; De Witt D; Ashford M; Hrkach J; Zale S; Jewsbury PJ; Barry ST
Sci Transl Med; 2016 Feb; 8(325):325ra17. PubMed ID: 26865565
[TBL] [Abstract][Full Text] [Related]
2. Optimizing Therapeutic Effect of Aurora B Inhibition in Acute Myeloid Leukemia with AZD2811 Nanoparticles.
Floc'h N; Ashton S; Taylor P; Trueman D; Harris E; Odedra R; Maratea K; Derbyshire N; Caddy J; Jacobs VN; Hattersley M; Wen S; Curtis NJ; Pilling JE; Pease EJ; Barry ST
Mol Cancer Ther; 2017 Jun; 16(6):1031-1040. PubMed ID: 28292940
[TBL] [Abstract][Full Text] [Related]
3. Modeling Dose and Schedule Effects of AZD2811 Nanoparticles Targeting Aurora B Kinase for Treatment of Diffuse Large B-cell Lymphoma.
Floc'h N; Ashton S; Ferguson D; Taylor P; Carnevalli LS; Hughes AM; Harris E; Hattersley M; Wen S; Curtis NJ; Pilling JE; Young LA; Maratea K; Pease EJ; Barry ST
Mol Cancer Ther; 2019 May; 18(5):909-919. PubMed ID: 30872381
[TBL] [Abstract][Full Text] [Related]
4. A novel in situ hydrophobic ion paring (HIP) formulation strategy for clinical product selection of a nanoparticle drug delivery system.
Song YH; Shin E; Wang H; Nolan J; Low S; Parsons D; Zale S; Ashton S; Ashford M; Ali M; Thrasher D; Boylan N; Troiano G
J Control Release; 2016 May; 229():106-119. PubMed ID: 27001894
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic polymeric nanoparticles and the methods of making and using thereof: a patent evaluation of WO2015036792.
Sarvagalla S; Hsieh HP; Coumar MS
Expert Opin Ther Pat; 2016 Jul; 26(7):751-5. PubMed ID: 27167102
[TBL] [Abstract][Full Text] [Related]
6. Hypersensitivity to aurora kinase inhibitors in cells resistant against platinum- containing anticancer agents.
Akiyama M; Izumi H; Wang KY; Yamaguchi T; Kuma A; Kitamura N; Harada Y; Oya R; Yamaguchi K; Iwai Y; Kohno K
Anticancer Agents Med Chem; 2014; 14(7):1042-50. PubMed ID: 24521151
[TBL] [Abstract][Full Text] [Related]
7. Discovery, synthesis, and in vivo activity of a new class of pyrazoloquinazolines as selective inhibitors of aurora B kinase.
Mortlock AA; Foote KM; Heron NM; Jung FH; Pasquet G; Lohmann JJ; Warin N; Renaud F; De Savi C; Roberts NJ; Johnson T; Dousson CB; Hill GB; Perkins D; Hatter G; Wilkinson RW; Wedge SR; Heaton SP; Odedra R; Keen NJ; Crafter C; Brown E; Thompson K; Brightwell S; Khatri L; Brady MC; Kearney S; McKillop D; Rhead S; Parry T; Green S
J Med Chem; 2007 May; 50(9):2213-24. PubMed ID: 17373783
[TBL] [Abstract][Full Text] [Related]
8. Multi-kinase inhibitors, AURKs and cancer.
Cicenas J; Cicenas E
Med Oncol; 2016 May; 33(5):43. PubMed ID: 27038473
[TBL] [Abstract][Full Text] [Related]
9. Effects of AZD1152, a selective Aurora B kinase inhibitor, on Burkitt's and Hodgkin's lymphomas.
Mori N; Ishikawa C; Senba M; Kimura M; Okano Y
Biochem Pharmacol; 2011 May; 81(9):1106-15. PubMed ID: 21371446
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological inhibition of aurora-A but not aurora-B impairs interphase microtubule dynamics.
Lorenzo C; Liao Q; Hardwicke MA; Ducommun B
Cell Cycle; 2009 Jun; 8(11):1733-7. PubMed ID: 19395863
[TBL] [Abstract][Full Text] [Related]
11. SAR156497, an exquisitely selective inhibitor of aurora kinases.
Carry JC; Clerc F; Minoux H; Schio L; Mauger J; Nair A; Parmantier E; Le Moigne R; Delorme C; Nicolas JP; Krick A; Abécassis PY; Crocq-Stuerga V; Pouzieux S; Delarbre L; Maignan S; Bertrand T; Bjergarde K; Ma N; Lachaud S; Guizani H; Lebel R; Doerflinger G; Monget S; Perron S; Gasse F; Angouillant-Boniface O; Filoche-Rommé B; Murer M; Gontier S; Prévost C; Monteiro ML; Combeau C
J Med Chem; 2015 Jan; 58(1):362-75. PubMed ID: 25369539
[TBL] [Abstract][Full Text] [Related]
12. The selective Aurora B kinase inhibitor AZD1152 as a novel treatment for hepatocellular carcinoma.
Aihara A; Tanaka S; Yasen M; Matsumura S; Mitsunori Y; Murakata A; Noguchi N; Kudo A; Nakamura N; Ito K; Arii S
J Hepatol; 2010 Jan; 52(1):63-71. PubMed ID: 19913935
[TBL] [Abstract][Full Text] [Related]
13. Effects of selective inhibitors of Aurora kinases on anaplastic thyroid carcinoma cell lines.
Baldini E; Tuccilli C; Prinzi N; Sorrenti S; Antonelli A; Gnessi L; Morrone S; Moretti C; Bononi M; Arlot-Bonnemains Y; D'Armiento M; Ulisse S
Endocr Relat Cancer; 2014 Oct; 21(5):797-811. PubMed ID: 25074669
[TBL] [Abstract][Full Text] [Related]
14. AMG 900, a potent inhibitor of aurora kinases causes pharmacodynamic changes in p-Histone H3 immunoreactivity in human tumor xenografts and proliferating mouse tissues.
Juan G; Bush TL; Ma C; Manoukian R; Chung G; Hawkins JM; Zoog S; Kendall R; Radinsky R; Loberg R; Friberg G; Payton M
J Transl Med; 2014 Nov; 12():307. PubMed ID: 25367255
[TBL] [Abstract][Full Text] [Related]
15. The aurora B kinase inhibitor AZD1152 sensitizes cancer cells to fractionated irradiation and induces mitotic catastrophe.
Tao Y; Leteur C; Calderaro J; Girdler F; Zhang P; Frascogna V; Varna M; Opolon P; Castedo M; Bourhis J; Kroemer G; Deutsch E
Cell Cycle; 2009 Oct; 8(19):3172-81. PubMed ID: 19755861
[TBL] [Abstract][Full Text] [Related]
16. Aurora kinase inhibitor AZD1152 negatively affects the growth and survival of HTLV-1-infected T lymphocytes in vitro.
Tomita M; Tanaka Y; Mori N
Int J Cancer; 2010 Oct; 127(7):1584-94. PubMed ID: 20091867
[TBL] [Abstract][Full Text] [Related]
17. AZD1152 negatively affects the growth of anaplastic thyroid carcinoma cells and enhances the effects of oncolytic virus dl922-947.
Libertini S; Abagnale A; Passaro C; Botta G; Barbato S; Chieffi P; Portella G
Endocr Relat Cancer; 2011 Feb; 18(1):129-41. PubMed ID: 21071467
[TBL] [Abstract][Full Text] [Related]
18. Aurora Kinase Inhibitors in Head and Neck Cancer.
Qi G; Liu J; Mi S; Tsunematsu T; Jin S; Shao W; Liu T; Ishimaru N; Tang B; Kudo Y
Curr Top Med Chem; 2018; 18(3):199-213. PubMed ID: 29332580
[TBL] [Abstract][Full Text] [Related]
19. The selective Aurora B kinase inhibitor AZD1152 is a potential new treatment for multiple myeloma.
Evans RP; Naber C; Steffler T; Checkland T; Maxwell CA; Keats JJ; Belch AR; Pilarski LM; Lai R; Reiman T
Br J Haematol; 2008 Feb; 140(3):295-302. PubMed ID: 18076711
[TBL] [Abstract][Full Text] [Related]
20. Preclinical FLT-PET and FDG-PET imaging of tumor response to the multi-targeted Aurora B kinase inhibitor, TAK-901.
Cullinane C; Waldeck KL; Binns D; Bogatyreva E; Bradley DP; de Jong R; McArthur GA; Hicks RJ
Nucl Med Biol; 2014 Feb; 41(2):148-54. PubMed ID: 24332383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]